Dean L. Schorno - Jan 24, 2022 Form 4 Insider Report for RIGEL PHARMACEUTICALS INC (RIGL)

Role
EVP &Chief Financial Officer
Signature
/s/ Dolly Vance (Attorney-in-Fact)
Stock symbol
RIGL
Transactions as of
Jan 24, 2022
Transactions value $
$0
Form type
4
Date filed
1/26/2022, 07:47 PM
Previous filing
Nov 5, 2021
Next filing
Sep 16, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RIGL Common Stock Award $0 +50K +63.36% $0.00 129K Jan 24, 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RIGL Stock Option (Right to Buy) Award $0 +100K $0.00 100K Jan 24, 2022 Common Stock 100K $2.42 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall vest annually over four (4) years from February 1, 2022, with the first annual vest occurring on February 1, 2023.
F2 Includes 28,908 shares acquired under the Issuer's stock purchase plan.
F3 The shares of common stock subject to the option vest monthly over four (4) years from the vesting commencement date of January 1, 2022, subject to the reporting person's continuous service to the issuer through each such period.